Reuters logo
BRIEF-Merck KGaA says IIIb study of Kuvan reached primary endpoint
April 24, 2014 / 6:22 AM / 3 years ago

BRIEF-Merck KGaA says IIIb study of Kuvan reached primary endpoint

FRANKFURT, April 24 (Reuters) - Merck KGaA : * Announces positive outcome of iiib study for kuvan * Says positive outcome of study will enable submission of regulatory

application for a label extension later this year

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below